[Vasculitis management: discovery of antineutrophil cytoplasmic antibodies (ANCA)].
Guillevin
Loïc
L
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; D015267:Churg-Strauss Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D003937:Diagnosis, Differential; D004195:Disease Models, Animal; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051379:Mice; D010488:Polyarteritis Nodosa / Q000175:diagnosis; D000069283:Rituximab; D014657:Vasculitis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*
D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab